25.01.10 09:35 Age: 47 days
IPSOGEN Obtains Option to Acquire License on TET2 abnormalities to improve the Diagnosis of Blood-based Disorders
Category: Leukemia
IPSOGEN today announces the signature of an option agreement for the worldwide and exclusive license on genomic abnormalities in the TET2 gene.
The scientific corpus supporting these TET2 patent rights has been developed by a consortium of 7 public institutions led by IGR&D, the technology transfer affiliate of Institut Gustave Roussy (IGR).
More
